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Obesity and cancer: the role of vitamin D
Thurkaa Shanmugalingam1*†, Danielle Crawley1,2†, Cecilia Bosco1, Jennifer Melvin1, Sabine Rohrmann3,
Simon Chowdhury2, Lars Holmberg1,4,5 and Mieke Van Hemelrijck1
Abstract
Background: It is estimated that 20% of all cancer cases are caused by obesity. Vitamin D is thought to be one of
the mechanisms underlying this association. This review aims to summarise the evidence for the mediating effect
of vitamin D on the link between obesity and cancer.
Methods: Three literature searches using PubMed and Embase were conducted to assess whether vitamin D plays
an important role in the pathway between obesity and cancer: (1) obesity and cancer; (2) obesity and vitamin D;
and (3) vitamin D and cancer. A systematic review was performed for (1) and (3), whereas a meta-analysis including
random effects analyses was performed for (2).
Results: (1) 32 meta-analyses on obesity and cancer were identified; the majority reported a positive association
between obesity and risk of cancer. (2) Our meta-analysis included 12 original studies showing a pooled relative risk
of 1.52 (95% CI: 1.33-1.73) for risk of vitamin D deficiency (<50 nmol/L) in obese people (body mass index >30 kg/m2).
(3) 21 meta-analyses on circulating vitamin D levels and cancer risk were identified with different results for different
types of cancer.
Conclusion: There is consistent evidence for a link between obesity and cancer as well as obesity and low vitamin D.
However, it seems like the significance of the mediating role of vitamin D in the biological pathways linking obesity
and cancer is low. There is a need for a study including all three components while dealing with bias related to dietary
supplements and vitamin D receptor polymorphisms.
Keywords: Cancer, Obesity, Vitamin D
Background
Over recent decades, the increasing prevalence of obes-
ity has been implicated in the risk of cancer incidence
and mortality [1-3]. The link between obesity and cancer
mortality is well-established [4,5]. A prospective cohort
study including >900,000 adults in the U.S, estimated
that being overweight or obese could account for 14% of
deaths from cancer in men and 20% in women [6]. In
the UK, an estimated 17,294 excess cancer cases occur-
ring in 2010, were due to overweight and obesity (5.5%
of all cancers) [7]. However, the mechanisms that link
excess body weight and carcinogenesis are not fully elu-
cidated. Vitamin D is one of the factors suggested to
play a role in this pathway [8], but the nature of this
association is not fully understood [2]. The immune
system and vitamin D receptor (VDR) are only two of the
suggested mechanisms for a link between vitamin D and
cancer which may also be connected to obesity [9-12].
To evaluate whether vitamin D explains how obesity
affects cancer risk, one needs to assess if vitamin D is a
mediator variable for the association between obesity
(exposure) and cancer (outcome) [13,14]. In a traditional
epidemiological approach, mediation analyses would es-
timate the excess risk of obesity on cancer explained by
vitamin D, by calculating the risk ratio for the associ-
ation between obesity and cancer in a crude model, and
a model adjusted for vitamin D [13]. To our knowledge,
no mediation analyses have been published to date for
this question, with the exception of one study focusing
on breast cancer-specific mortality and one study esti-
mating the attributable fraction of vitamin D in obese
people [1,15]. These studies were not set out as medi-
ation analyses, but suggested that low vitamin D levels
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contribute to about 16 to 20% of the increased cancer
incidence or mortality from breast cancer in overweight
and obese patients [1,15]. This is in contrast with find-
ings from large cohort studies suggesting no association
between vitamin D and breast cancer [16].
We approached the issue of mediation by vitamin D
with a literature review for each association with the
question of whether vitamin D plays an important role
in the pathway between obesity and cancer (Figure 1):
(1) obesity and cancer; (2) obesity and vitamin D; and
(3) vitamin D and cancer, while addressing some of the
methodological issues. Many meta-analyses have been
done for (1) and (3), but limited pooled results are avail-
able for (2). Hence, we performed a meta-analysis for
the association between obesity and vitamin D.
Methods
Obesity and cancer
A comprehensive literature review of all published meta-
analyses on the association between obesity and cancer
was carried out. We used computerised search databases
(PubMed search followed by an Embase search) to iden-
tify full text and abstracts focused on human subjects
and published in English language within the last fifteen
years. Searches were conducted both with and without
MeSH terms for “obesity”, “cancer” and “meta-analysis”.
This search was repeated for individual cancer types:
“breast”, “colorectal”, “melanoma”, “oesophageal”, “liver”,
“lung”, “ovarian”, “endometrial”, “prostate”, “pancreatic”
and “kidney” cancer. Although lung cancer may not be
the obvious cancer to investigate in the context of obes-
ity [17,18], some studies [19,20] reported a positive asso-
ciation while others are inconclusive or conflicting.
Hence, lung cancer was also included in this literature
review.
Obesity and vitamin D: a meta-analysis
Literature search strategy
We used computerised search databases (PubMed search
followed by an Embase search) to identify full text and ab-
stracts published within the last fifteen years, of English
language and used human subjects. The searches were
performed with and without MeSH terms for “vitamin D”,
“25 hydroxyvitamin D”, “obesity”, and “body mass index”.
We also included “grey literature” such as abstracts, let-
ters, and articles presented at relevant conferences and
meetings. All references of the selected articles were
checked using hand searches.
Inclusion criteria
All included studies were of epidemiological nature: co-
hort, case–control, or cross-sectional. Furthermore, all
studies included measurements of vitamin D and body
mass index (BMI) and assessed the association between
the two. We only included those studies with a sufficient
power, deemed as including more than twenty cancer
cases. Obesity, defined as BMI >30 kg/m2, was the main
exposure of interest. Low vitamin D levels were the out-
come, defined using a cut off of <50 nmol/L, which en-
compasses both vitamin D insufficiency and deficiency.
Initially, titles and abstracts of articles were reviewed
by two researchers (Thurkaa Shanmugalingam - TS and
Danielle Crawley - DC). If they met initial inclusion cri-
teria both abstract and full text article were reviewed to
ascertain whether all inclusion criteria were met. A de-
tailed evaluation of methods and results was undertaken.
In the case of any disagreement between the two re-
searchers on article inclusion assessments, the full text
article was reviewed by a third researcher (Mieke Van
Hemelrijck - MVH). Figure 2 illustrates the study exclu-
sion process.
Figure 1 Overview of vitamin D as a potential mediator for the association between obesity and cancer. Abbreviations: TS, Thurkaa
Shanmugalingam; DC, Danielle Crawley; BMI, body mass index.
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Data extraction
The following details were recorded for each study: au-
thor, year of publication, country, type of study, method
of vitamin D measurement, statistical tests used, number
of subjects with sufficient, insufficient and deficient vita-
min D status and BMI of all subjects.
Statistical methods
The association between obesity and vitamin D levels
was evaluated by calculating the pooled relative risk
(RR) with random effects model to allow for possible
heterogeneity between studies. Potential publication bias
was evaluated using Beggs Test and Eggers funnel plot.
All analyses were performed with STATA version 11.0.
Vitamin D and cancer
A comprehensive literature search of all meta-analyses
conducted on the association between vitamin D and
cancer was performed. We used computerised search da-
tabases (PubMed search followed by an Embase search) to
identify full text and abstracts focused on human subjects
and published in English language within the last fifteen
years. Searches were conducted both with and with-
out MeSH terms for “vitamin D”, “cancer”, “vitamin D
receptor”, “polymorphism” and “meta-analysis”. This search
was repeated for specific cancer types: “breast”, “colorectal”,
“melanoma”, “oesophageal”, “liver”, “lung”, “ovarian”, “en-
dometrial”, “prostate”, “pancreatic” and “kidney” cancer.
Moreover, we also searched clinicaltrials.gov for clin-
ical trials focused on “vitamin D supplements” and “can-
cer” or “neoplasm” [21].
Results
Obesity and cancer
Thirty-two meta-analyses were identified from our lit-
erature search on obesity and cancer (Table 1). More
specifically, all seven meta-analyses on colorectal cancer
showed a positive association between BMI and colo-
rectal cancer risk [22-28]. When looking at site-specific
cancer within colorectal cancer, BMI was only signifi-
cantly associated with rectal cancer in males. Also upper
gastro-intestinal cancers (oesophageal, oesophageal gas-
tric junction, gastric and gall bladder cancer) were posi-
tively associated with obesity [29-32]. The strongest link
was seen for oesophageal cancer with over a two-fold
increased risk reported [29,32]. All four meta-analyses
on liver cancer reported an increased risk with increas-
ing BMI [33-36], whereas the lung cancer meta-analysis
Figure 2 Flowchart of study selection for the association of obesity and vitamin D.
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Table 1 Summary of relative risks from meta-analyses on the association between obesity and risk of cancer
Author/Year Pooled RR (95% CI) Number and type of studies included
Colorectal
Ma Y et al., 2013 1.334 (1.253-1.420) 41 prospective studies
Matsuo K et al., 2012 Per 1 kg/m2: 1.03 (1.02-1.04); Males: 1.02
(1.00-1.03); Females: 1.02 (1.00-1.03)
8 cohort studies
Ning Y et al., 2010 Per 5 kg/m2: 18% increased risk 56 studies
Harriss DJ et al., 2009 Per 5 kg/m2: 1.24 (1.20-1.28) 3 ca/co and 26 cohort studies
Moghaddam AA et al., 2007 1.19 (1.11-1.29) 23 cohort and 8 ca/co studies
Dai Z et al., 2007 Males: 1.37 (1.21-1.56); Females: 1.07 (0.97-1.18) 15 cohort studies
Larsson SC et al., 2007 (Am J Clin Nutr) Per 5 kg/m2: Males: 1.30 (1.25-1.35); Females 1.12 (1.07-1.18) 30 prospective studies
Upper Gastrointestinal
Hoyo C et al., 2012 2.39 (1.86-3.06) 12 ca/co studies
Yang P et al., 2009 1.22 (1.06-1.41) 10 cohort studies
Larsson SC et al., 2007 (Br J Cancer, Vol.96) 1.66 ( 1.47-1.88) 3 ca/co and 8 cohort studies
Kubo A et al., 2006 Males: 2.40 (1.90-3.20); Females: 2.10 (1.40-3.20) 2 cohort and 12 ca/co studies
Liver
Rui R et al., 2012 1.35 (1.24-1.47) 12 prospective studies
Chen Y et al., 2012 1.83 (1.59-2.11) 26 prospective studies
Larsson SC et al., 2007 (Br J Cancer, Vol.97) 1.89 (1.51-2.36) 11 cohort studies
Wang Y et al., 2012 Per 5 kg/m2: 1.39 (1.25-1.55) 21 prospective studies
Lung
Yang Y et al., 2013 0.79 (0.73-0.85) 20 cohort and 11 ca/co studies
Pancreatic
Aune D et al., 2012 Per 5 kg/m2: 1.10 (1.07-1.14) 23 prospective studies
Genkinger JM et al., 2011 1.30 (1.09-1.56) 14 cohort studies
Jiao L et al., 2010 1.19 (1.05-1.35) 7 prospective cohorts
Berrington de Gonzalez A et al., 2003 1.19 (1.10-1.29) 8 cohort and 6 ca/co studies
Kidney
Mathew A et al., 2009 Per unit BMI: Cohorts: 1.06 (1.05-1.07); ca/co: 1.07 (1.06-1.08) 15 cohort and 13 ca/co studies
Bergström A et al., 2001 Per unit BMI: 1.07 (1.05-1.09) 6 cohort and 22 ca/co studies
Bladder
Qin Q et al., 2013 1.10 (1.06-1.16) 11 cohort studies
Prostate
Discacciati A et al., 2012 Locally advanced per 5kg/m2 0.94 (0.91-0.99);
Advanced 1.09 (1.02-1.16)
25 prospective studies
MacInnis RJ et al., 2006 Per 5 kg/m2: 1.05 (1.01-1.08) 31 cohort and 25 ca/co studies
Breast
Cheraghi Z et al., 2012 Pre-menopausal: 0.93 (0.86-1.02); Post-menopausal: 1.15 (1.07-1.24) 50 studies
Pierobon M et al., 2013 1.20 (1.03-1.40); Pre-menopausal: 1.43 (1.23-1.65);
Post–menopausal: 0.99 (0.79-1.24)
11 ca/co studies
Key TJ et al., 2003 1.36 (1.10-1.85) 8 prospective studies
Ovarian
Olsen CM et al., 2007 1.30 (1.10-1.50) 13 ca/co and 12 cohort studies
Endometrial
Esposito K et al., 2014 2.21 (1.50-3.24) 4 ca/co and 1 cohort studies
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reported an inverse association with obesity (RR: 0.79;
95% CI: 0.73-0.85) [20]. Meta-analyses on pancreatic
cancer reported a positive association with obesity
[37-40], which is parallel to the conclusions that can be
drawn for kidney cancer [41,42]. For prostate cancer
[43], a protective effect of obesity was reported for local-
ised disease, whereas obesity was positively associated with
metastatic disease [44]. The meta-analysis on bladder
cancer reported a positive association even when adjust-
ment for smoking was performed [45]. Some variation
was observed for breast cancer depending on menopausal
status and breast cancer subtype [46,47]. A positive associ-
ation between obesity and breast cancer was more distinct
among postmenopausal women [48]. The meta-analysis
on ovarian cancer reported a positive association with
obesity, with no difference in the histological subtypes of
ovarian cancer studied [49]. As for the majority of other
cancers [50], there was also a positive association found
for endometrial cancer [51]. However, this meta-analysis
included some studies which used waist circumference as
a measure of obesity instead of BMI [51]. The meta-
analysis on melanoma reported a positive association in
men (RR: 1.31; 95% CI: 1.19-1.44), but not in women
(RR: 0.99; 95% CI 0.83-1.18) [52].
Obesity and vitamin D
The initial PubMed search produced a total of 356
(TS) and 352 (DC) papers. Further assessment of
abstracts and papers based on the above-defined
inclusion criteria (Figure 2) resulted in inclusion of
12 studies for primary data analysis (three cohorts,
two case–control and seven cross-sectional studies)
(Table 2).
The random effects analyses showed a pooled relative
risk of 1.52 (95% CI: 1.33-1.73) for the association
between obesity and low vitamin D status (Figure 3).
The I2 statistic suggested heterogeneity (I2 = 89.4%).
There was no difference between those studies looking
at children and adolescents combined and those
looking at an adult population (RR: 1.52; 95% CI:
1.04-2.26 and 1.53; 95% CI: 1.31-1.80, respectively).
Beggs and Eggers test was used to evaluate publica-
tion bias with the funnel plot suggesting the study by
Goldner et al. to be an outlier [53] (Results not
shown). We performed a sensitivity analysis by exclud-
ing this study from our analysis. The pooled estimate
of RR did not change drastically, although the link was
strengthened to some extent (RR: 1.34; 95% CI: 1.15-
1.57).
Table 1 Summary of relative risks from meta-analyses on the association between obesity and risk of cancer
(Continued)
Melanoma
Sergentanis TN et al., 2013 Males: 1.31 (1.19-1.44); Females: 0.99 (0.83-1.18) 11 ca/co and 10 cohort studies
All cancers
Renehan AG et al., 2008 Per 5kg/m2: Men: Oesophageal: 1.52 (1.33-1.74); Thyroid:
1.33 (1.04-1.70); Colon: 1.24 (1.20-1.28); Renal: 1.24 (1.15-1.34)
141 studies
Per 5kg/m2: Women: Endometrial: 1.59 (1.50-1.68); Gallbladder:
1.59 (1.02-2.47); Oesophageal: 1.51 (1.31-1.74); Renal: 1.34 (1.25-1.43)
Abbreviations: RR relative risk, BMI body mass index, ca/co case–control.
Table 2 Summary of studies included in meta-analysis on obesity and vitamin D status
Author/ Year Country Sex Type of study Study size
Mai XM et al., 2012 Norway Both Cohort 2460 subjects
Goldner WS et al., 2008 USA Both Case/control 41 cases/41 controls
Hyppönen E et al., 2006 UK Both Cohort 7,198 subjects
Al-Sultan AI et al., 2011 Saudi Arabia Both Case/control 76 cases / 84 controls
Campagna AM et al., 2013 USA Both Cohort 1,378 subjects
Turer CB et al., 2013 USA Both Cross-sectional 12,292 subjects
Guasch A et al., 2012 Spain Both Cross-sectional 316 subjects
Poomthavorn P et al., 2012 Thailand Both Cross-sectional 179 subjects
Olson ML et al., 2012 USA Both Cross-sectional 411 cases/ 87 controls
Shea MK et al., 2011 USA Both Cross-sectional 2581 subjects
Elizondo-Montemayor L et al., 2010 Mexico Both Cross-sectional 198 subjects
Cizmecioglu FM et al., 2008 Turkey Both Cross-sectional 301 subjects
Abbreviations: USA United States of America, UK United Kingdom.
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Vitamin D and cancer
From the literature search, we identified 21 meta-analyses
on the association between circulating vitamin D levels and
cancer risk (Table 3), showing different results for different
types of cancer. We found 34 clinical trials investigating the
effect of vitamin D supplementation on cancer (Table 4)
[21]. From these, two studies were terminated, 18 are active,
13 have been completed, and one has an unknown status.
All six meta-analyses on colorectal cancer reported that
circulating vitamin D levels were inversely associated with
cancer risk [54-59]. A pooled analysis from multiple cohort
studies on pancreatic cancer, suggested no significant
association for participants with low vitamin D levels.
Those with vitamin D levels ≥100 mmol/L were at a statis-
tically significant twofold increase in pancreatic cancer
compared to those with normal vitamin D levels [60]. The
pooled analysis for kidney cancer only found a statistically
significant decreased cancer risk among women when vita-
min D levels was ≥75 nmol/L [61]. In contrast, all three
meta-analyses on prostate cancer found no evidence for
an inverse association with vitamin D levels [58,62,63].
Results from four out of five meta-analyses showed an
inverse association for breast cancer, with the highest
quartile of vitamin D levels decreasing the risk of breast
cancer [58,64-67] compared to the lowest quartile. How-
ever, it is interesting to note that case–control studies
generally report an inverse association, whereas nested case
control studies reported null-findings [58,64-67]. The meta-
analysis on ovarian cancer reported a non-statistically
significant inverse association with high serum vitamin D
levels [68]. Finally, the meta-analysis on total cancer
incidence and mortality reports a moderate inverse
relationship with circulating vitamin D concentrations [69].
From the 13 completed clinical trials evaluating the
effect of vitamin D supplementation on cancer risk, only
two have reported results [70,71]. One randomised trial
focused on risk of colorectal cancer over a period of seven
years in a double-blinded, placebo-controlled setting, where
one group of postmenopausal women received calcium and
vitamin D3 supplementation and the other group received
placebo [70]. The study found no statistically significant
effects of calcium or vitamin D3 supplementation on the
incidence of colorectal cancer. The other completed trial
had a similar design, but focused on risk of all cancers in
postmenopausal woman receiving 1400–1500 mg supple-
mental calcium/d alone, supplemental calcium plus 1100 IU
Figure 3 Forest plot for the association between obesity and low vitamin D levels.
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vitamin D3/d, or placebo during a follow-up of four
years [71]. In contrast, this trial found that those women
on vitamin D supplementation had a lower risk of
cancer, compared to the placebo group when the
analysis was confined to cancers diagnosed after the first
12 months (RR: 0.23; 95% CI: 0.09-0.60). No statistical
analyses were performed for specific types of cancer
[71].
Discussion
To date no mediation analyses have been performed for
the effect of obesity on cancer risk through vitamin D.
Even though we could not find the question addressed
in one single study, it is still of interest to discuss study
design and methodology of studies published on any of
the three questions, (Figure 1) to interpret the validity of
a potential mediation effect of vitamin D [72].
Obesity and cancer
The majority of meta-analyses included in our review re-
ported positive associations between obesity and risk of
cancer, showing that the strength of this association varies
between cancer sites, sex, and in breast cancer, the meno-
pausal status. The World Cancer Research Fund (WCRF)
Table 3 Summary of relative risks from meta-analyses on the association between vitamin D status and risk of cancer
Cancer Study, publication year Country No. of subjects;
Type of study
RR (95% CI) Notes Measure/Range of
vitamin D
Breast Bauer SR et al., 2013 USA 11,656; 9 prospective 0.99 (0.97-1.04) Pre-menopausal 17-33.1 ng/mL (Mean)
Bauer SR et al., 2013 USA 11,656; 9 prospective 0.97 (0.93-1.00) Post-menopausal 17-33.1 ng/mL (Mean)
Yin L et al., 2010 Germany Case-control 0.74 (0.69-0.80) By 20 ng/mL increase
Chen P et al., 2010 China 11,330; 4 case-control/3
nested case-control
0.55 (0.38-0.80) Top vs. bottom quantiles
(varies)
Gandini S et al., 2011 France 10 studies 0.89 (0.81-0.98) By 10 ng/mL increase
Chen P et al., 2013 China 26,317; 21 studies 0.52 (0.40-0.68) By 1 ng/mL increase
Kidney Gallicchio L et al., 2010 USA 1,550; 8 cohorts 1.12 (0.79-1.59) Low <37.5 nmol/L <37.5 vs. 50-<75 (ref) nmol/L
Gallicchio L et al., 2010 USA 1,550; 8 cohorts 1.01 (0.65-1.58) High ≥75 nmol/L ≥75 vs. 50-<75 (ref) nmol/L
Pancreatic Stolzenberg-Solomon RZ
et al., 2010
USA 2,285; 8 cohorts 0.96 (0.66-1.40) Low <25 nmol/L <25 vs. 50-<75 (ref) nmol/L
Stolzenberg-Solomon RZ
et al., 2010
USA 2,285; 8 cohorts 2.14 (0.93-4.92) High ≥100 nmol/L ≥100 vs. 50-<75 (ref) nmol/L
Colorectal Touvier M et al., 2011 UK 6 studies 0.96 (0.94-0.97) 200-1,800 IU/L
Lee JE et al., 2011 USA 8 prospective 0.66 (0.54-0.81) Top vs. bottom quantiles
(varies)
Ma Y et al., 2011 China 6,715; 9 studies 0.67 (0.54-0.80) Top vs. bottom categories
(varies)
Yin L et al., 2009
(Aliment Pharmacol Ther)
Germany 3,556; 8 studies 0.57 (0.43-0.76) By 20 ng/mL increase
Gorham ED et al., 2007 USA 1,448; 5 nested
case–control
0.49 (0.35-0.68) Top vs. bottom quintile
(varies)
Gandini S et al., 2011 France 9 studies 0.85 (0.79-0.91) By 10 ng/mL increase
Prostate Gilbert R et al., 2011 UK 14 cohort/nested
case–control
1.04 (0.99-1.10) By 10 ng/mL increase
Yin L et al., 2009
(Cancer Epidemiol)
Germany 7,806; 11 studies 1.03 (0.96-1.11) By 10 ng/mL increase
Gandini S et al., 2011 France 11 studies 0.99 (0.95-1.03) By 10 ng/mL increase
Ovarian Yin L et al., 2011 Germany 2,488; 10 longitudinal 0.83 (0.63-1.08) By 20 ng/mL increase
All Cancers Yin L et al., 2013 Germany 5 studies 0.89 (0.81-0.97) Total cancer
incidence
Per 50nmol/L increase
13 studies 0.83 (0.71-0.96) Total cancer mortality Per 50nmol/L increase
3 studies 0.76 (0.60-0.98) Total cancer mortality
(women)
Per 50nmol/L increase
5 studies 0.92 (0.65-1.32) Total cancer mortality
(men)
Per 50nmol/L increase
Abbreviations: RR relative risk, USA United States of America, UK United Kingdom, ref reference.
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suggests that obesity is associated with increased risk of
oesophageal adenocarcinoma, pancreatic, colorectal, post-
menopausal breast, endometrial and renal cancer [73].
There are several molecular mechanisms suggested to
explain the increased risk of cancer in obese people. The
most commonly postulated being the “insulin–cancer
hypothesis” [74], suggesting that obesity results in chro-
nic hyperinsulinaemia. Prolonged hyperinsulinaemia leads
to raised insulin like growth factor 1 (IGF-1) levels, which
are known to produce cellular changes leading to carcino-
genesis via increased mitosis and reduced apoptosis. Sec-
ondly, in hormonally-driven cancers, such as endometrial
Table 4 Summary of clinical trials on vitamin D status and cancer risk
Cancer NCT# Country No. of subjects Intervention Status Main finding
Colorectal NCT00870961 USA 22 VDS Terminated Not reported
Colon NCT00470353 USA 8 VDS, CaCO3 Terminated Not reported
Lung NCT01631526 Canada 80 VDS Active recruitment
Colorectal NCT01074216 USA 49 VDS Active, not recruiting
Not specified NCT01169259 USA 20,000 VDS, fish oil Active recruitment
Not specified NCT01463813 Finland 18,000 VDS Active recruitment
Prostate NCT0887432 USA 100 VDS Active recruitment
Colorectal NCT01516216 USA 120 VDS, folfox, bevacizumab Active recruitment
Ovarian NCT01744821 USA 80 VDS Active recruitment
Breast NCT01224678 USA 180 VDS Active, not recruiting
Colon, prostate NCT00585637 USA 328 VDS Active, not recruiting
Lymphoma, leukaemia,
colon, breast, rectal
NCT01787409 USA 956 VDS Active, not recruiting
Breast NCT01747720 Canada 376 VDS Active recruitment
Breast, leukaemia, colon,
lymphoma, lung, myeloma
NCT01052051 USA 2,300 VDS Active, not recruiting
Prostate NCT01325311 USA 50 VDS, genistein Active recruitment
Prostate NCT00022412 USA 60 VDS Active, not recruiting
Breast NCT01097278 USA 200 VDS Active recruitment
Breast NCT01816555 USA 20 VDS Active recruitment
Leukaemia NCT01521936 USA 4 VDS Active, not recruiting
Solid tumours NCT00004926 USA NA VDS Completed Not reported
Leukaemia, myeloma NCT00068276 USA NA VDS Completed Not reported
Prostate NCT00004928 USA NA VDS, zoledronate Completed Not reported
Colorectal NCT01574027 USA 55 VDS Completed Not reported
Breast NCT01240213 USA 218 VDS Completed Not reported
Colorectal NCT00208793 USA 92 VDS Completed Not reported
Colon NCT00298545 USA 10 VDS, calcium Completed Not reported
Prostate NCT01045108 USA 52 VDS Completed Not reported
Prostate NCT00524680 USA 128 VDS Completed Not reported
Pancreatic NCT00238199 USA 25 VDS, docetaxel Completed Not reported
Prostate NCT00004043 USA 25 VDS Completed Not reported
Breast, colon NCT00000611 USA 18,176 VDS, CaCO3 Completed No effect
Not specified NCT00352170 USA 1,179 VDS, CaCO3 Completed All-cancer risk reduction
Colorectal NCT01150877 Canada 40 VDS Unknown
Prostate NCT00741364 Canada 90 VDS Unknown
Prostate NCT00482157 USA 24 VDS Unknown
Colorectal NCT01403103 NA 0 VDS Withdrawn
Abbreviations: NCT# national clinical trial number, USA United States of America, VDS vitamin D supplement, CaCO3 calcium carbonate, NA not applicable.
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and post-menopausal breast cancer, the increased risk
may be partly explained by an increase in circulating levels
of sex steroid hormones. In the post-menopausal state, the
majority of oestrogen is derived from adipose tissue rather
than from the ovaries, potentially explaining the discrep-
ancy between pre- and post-menopausal women. Thirdly,
obesity is thought to result in a state of chronic inflamma-
tion and this has an effect on the cytokine microenviron-
ment. These changes lead to an increase in tumour cell
motility, invasion and metastasis. The change in the cyto-
kine milieu has been suggested as a possible mechanism
in several cancers including post-menopausal breast
cancer [75].
The majority of the meta-analyses in our literature re-
view included a substantial number of studies, with con-
sistent study design. However, the meta-analysis on
endometrial cancer [51] only included five studies of
which some used other markers than BMI to define obes-
ity (i.e. waist circumference). None of the studies to date
included additional information on vitamin D status.
In summary, there is consistent accumulating evidence
for an association between obesity and risk of certain can-
cer with several suggested molecular mechanisms that can
potentially explain these raised risks. However, the role of
vitamin D is not addressed in detail in these studies.
Obesity and vitamin D
To our knowledge this is the largest meta-analysis to
date on the association between circulating vitamin D
levels and obesity. The pooled estimates suggest an in-
verse relationship between vitamin D and obesity.
The possible relationship between vitamin D and obes-
ity was firstly described by Rosenstreich et al. in 1971
[76], who suggested that adipose tissue serves as a large
storage site for vitamin D to protect against toxicity from
vitamin overdose. The inverse association between obesity
and vitamin D is thus thought to be a result of increased
metabolic clearance in adipose tissue [77]. However, it has
recently been suggested that this association is more com-
plex since bariatric surgery solely has temporary effect on
improving circulating vitamin D levels [78]. It is also pos-
tulated that obese individuals are less likely to engage in
outdoor physical activity and dress differently than non-
obese individuals, hence leading to decreased sun ex-
posure [79,80]. Wortsman et al. have shown that the
bioavailability of cutaneously synthesised vitamin D
decreases by >50% in obese people [81]. Even though
exposure to sunlight is the main source of vitamin D
synthesis [82,83], its ultraviolet radiation is also known to
increase risk of developing malignant melanoma of the
skin [83]. In general, epidemiological studies have de-
scribed that the highest incidence of melanoma is seen in
fair-skinned population living closest to the equator
[82,84]. Within this population the highest risk is seen in
those who report sunburn or intermittent sun exposure
[85-87]. Furthermore, Newton-Bishop et al. found that
low vitamin D levels were associated with a thicker and
more aggressive melanoma, with a poorer outcome [88].
Overall, vitamin D levels are known to be lower in obese
individuals and several studies have observed that in-
creased BMI is associated with an increased risk of devel-
oping melanoma [89-91]. However, to date it has not been
clarified whether the risk of melanoma in obese individ-
uals is due to lower vitamin D levels associated with high
BMI or less sun exposure.
Furthermore, certain vitamin D receptor (VDR) poly-
morphisms are associated with obesity [92,93]. Upon
ligation with calcitriol, the VDR couples with the retin-
oid X receptor (RXR) forming the VDR/RXR complex.
This complex then further recruits other molecules, and
finally binds to vitamin D response elements in the nu-
cleus to activate the transcription of vitamin D target
genes [92,93]. Preclinical studies report expression of
human VDR in mature mice adipocytes. This results in
increased adipose mass and decreased energy expend-
iture [94] and expression of VDR in preadipocyte cell
lines; this inhibits adipocyte differentiation [95]. A posi-
tive association between obesity and the Taq1 gene was
also reported in a Greek case–control study [96].
In contrast, some suggest that low vitamin D itself
promotes obesity. Kong and Li demonstrated that vita-
min D levels may block the expression of downstream
adipocyte components such as fatty acid synthase, which
consequently suppresses adipogenesis [97]. One inter-
ventional study investigated the effects of vitamin D on
weight loss and showed that those with higher baseline
vitamin D experienced a greater degree of weight loss
than those with lower baseline vitamin D [98].
In conclusion, our meta-analysis reports a modest in-
verse association between obesity and low vitamin D
levels. The underlying biological mechanisms are un-
known. The majority of studies point towards the hy-
pothesis that, vitamin D stored in fat tissue increases
local vitamin D concentrations causing activation of the
VDR in adipocytes. This may lead to low energy usage
and further promotion of obesity [94].
Vitamin D and cancer
In this literature review only those meta-analyses focus-
ing on colorectal cancer found a consistent inverse asso-
ciation between circulating vitamin D levels and cancer
risk [54-59]. In contrast, of the two completed clinical
trials for which results are published to date, one showed
no effect on colorectal cancer risk and one showed a
protective effect for all cancer risk [70,71].
A protective effect of vitamin D in colorectal cancer was
first reported by Garland and Garland [99]. Despite the
inconsistency in epidemiological findings [54-61,64-68],
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there is preclinical evidence linking vitamin D and cancer,
suggesting that vitamin D has anti-proliferative effects via
mechanisms such as G0/G1 arrest, differentiation, and in-
duction of apoptosis [100].
More specifically, it is suggested that vitamin D has
anti-tumour effects through its binding with the VDR.
Several animal and cell culture models showed that VDR
plays a key role in the anticancer effects of circulating
vitamin D [9-11]. For instance, it has been reported that
downregulation of VDR correlates with poor prognosis
in colon cancer [101], suggesting that some of the discrep-
ancy observed in epidemiological studies can be explained
through gene polymorphisms [102]. VDR polymorphisms
have been associated, both positively and inversely, with
risk of cancer depending on the type of cancer, poly-
morphism, and other factors such as sun exposure or
circulating vitamin D levels [8,103]. For instance, a meta-
analysis for prostate cancer found no association between
the recessive genotype and the risk of prostate cancer rela-
tive to the dominant genotype of Fok1 [104]. To date, the
importance of the role of VDR polymorphisms in carci-
nogenesis is unclear [101], but when analysed with add-
itional factors like VDR haplotype combinations, vitamin
D serum levels and other confounders, polymorphisms
have been shown to play an important factor in can-
cer prognosis [105-107].
Interestingly, several parts of the immune system (i.e.
macrophages, neutrophils, or natural killer cells) also
express the VDR, but the related effects remain to be
elucidated [12]. It has for instance been suggested that
vitamin D can weaken antigen presentation by dendritic
cells, which results in suppression of their capacity to
activate T cells. Furthermore, activation of the VDR pro-
motes a shift towards T helper 2 responses, leading to
antibody-mediated immunity and promoting a chronic
state of disease [108,109]. Hence, it is plausible that vita-
min D has an immunosuppressive effect, which leaves
tumour cells without the necessary immunosurveillance
to stop them from proliferating. Thus, this suggests that
the above-described potential anti-cancer effect of vita-
min D most likely occurs through different mechanisms
than the immune system. Most literature to date on vita-
min D and the immune system has focused on auto-
immune and infectious diseases, with scarce literature
focusing on cancer.
In 2008, the International Agency for Research on
Cancer concluded that evidence for an association be-
tween vitamin D and cancer was inconclusive, and high-
lighted the need for a clinical trial with specific focus on
vitamin D and colorectal cancer [101]. The inconsistent
findings from two trials for which results are published
to date [70,71] may be explained by the lower dose of
vitamin D in the first study (i.e. 400 IU vs. 1100 IU).
Furthermore, baseline vitamin D levels were lower in the
second trial (i.e. 42 nmol/L vs. 71.8 nmol/L). Thus, despite
the large amount of preclinical studies trying to establish a
link between vitamin D and cancer, the contradictive find-
ings from large epidemiological studies indicate that it is
prudent to wait for more results from the 34 currently on-
going trials to draw a reliable conclusion.
Is vitamin D a mediator for the association between
obesity and cancer?
When assessing the three conditions required for vita-
min D to be a mediator we found only partial fulfilment
[110]. The literature shows consistent evidence for an
association between vitamin D and obesity. However,
there was lack of studies showing a consistent link be-
tween vitamin D and cancer after adjustment for obes-
ity. To date, only two clinical trials have published their
results with inconsistent findings. Furthermore, to our
knowledge no study has assessed the mediation effect of
vitamin D by quantifying the extent of obesity on can-
cer, which could be explained by a potential mediator.
Several other difficulties occur when assessing the me-
diation effect of vitamin D in the context of obesity and
cancer. Dichotomisation of vitamin D exposure (low ver-
sus normal) could lead to misclassification in exposure
levels. Those with extreme high values of vitamin D may
have been included in the “normal” group. Hence, bias
can occur when there is misclassification of the media-
tor [13]. Studies to date have used different cut-offs to
define vitamin D deficiency, which can potentially be
addressed with a dose–response assessment of this me-
diator. Unfortunately, it was not possible in this meta-
analysis to use dose–response data [111] as the number
of relevant studies available to date was small, and the
qualitative classifications of circulating vitamin D levels
varied. Furthermore, the effects of dietary supplements
on circulating vitamin D levels needs to be accounted
for, and very few studies took this into account [112].
The latter does not necessarily affect blood levels of
vitamin D, but it may influence the biological role of
vitamin D. Within-person variation may also affect the
results of our meta-analysis, as only one measurement
in time might not be representative of a person’s average
vitamin D level. Moreover, it is important to address po-
tential important confounders for the different asso-
ciations studied [13,72]. For instance, when evaluating
the effect of the mediator (vitamin D) on the outcome
(cancer), one has to consider age, sex, use of dietary
supplements, ethnic variations, calcium intake and sun
exposure [113], as they may be effect modifiers for the
association between obesity and vitamin D. It has been
argued that it is also important to address the strength
of the association between these mediator-exposure
confounders and both the exposure (obesity) and the
outcome (cancer) [13]. With respect to the mediation
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effect of vitamin D, one also needs to evaluate whether
there is a potential interaction affecting the link be-
tween the exposure (obesity) and the mediator (vitamin
D) [13]. Effect modification may also have an effect on
the link between the mediator (vitamin D) and the out-
come (cancer), as is suggested by the different polymor-
phisms affecting the VDR [8].
Additionally, the current systematic literature reviews
are prone to the heterogeneity related to observational
studies. For example, for the studies focused on vitamin
D and obesity the included studies recruited adults
residing in a particular town [114], from medical cen-
tres [115-117], from sample surveys [2,118], and those
undergoing bariatric surgery [53]. Children were recruited
from schools [119,120], hospitals [121,122], and sample
surveys [123]. Vitamin D levels were measured using
either an immunoassay [2,53,114,115,118-121,123] or
a high-performance liquid chromatography [116,122].
Anthropometric data, including weight, height, waist
circumference and BMI, were recorded for all participants
[119,120,122]. Furthermore, information on dietary, phy-
sical activity and sun exposure were collected either by
parental report during in-person interviews [123], and
interview-administered questionnaires [114,122]. These
questionnaires may be subject to recall bias, as partici-
pants may not always give accurate data [124,125] due to
the time interval, degree of detail, personal characteristics,
significance of events, social desirability or interviewing
techniques [126]. Furthermore, despite proven validation,
many food questionnaires have been found to be impre-
cise [127], due to the fact that people tend to answer these
type of questions based on what their dietary routines are,
more than on the real consumption. These memories are
usually influenced by sex, age, and concerns about weight
or body image [128].
A strength of these systematic reviews and meta-
analysis is that we made all possible efforts to include all
relevant publications available to date through various
sources, including grey literature, and the two main on-
line databases (PubMed and Embase). In addition, clearly
defined objective criteria for exposure, outcome, and other
study characteristics were specified a priori.
Conclusion
To understand how vitamin D may play a role in the
association between obesity and carcinogenesis, we as-
sessed the strength of these three associations: 1) There
was a consistent positive association between obesity
and cancer with relative risks varying between 1.10 and
1.90 when addressing the existing literature; (2) Our
new meta-analysis illustrated an association as strong
as 1.50 between obesity and low vitamin D levels; (3)
The literature for vitamin D status and cancer risk only
showed consistent evidence for an inverse association with
colorectal cancer. From these reviews, it seems that the
significance of the mediating role of vitamin D in the bio-
logical pathways linking obesity and cancer is low. This
review emphasises that further research specifically ad-
dressing the relationship between obesity, vitamin D and
cancer risk in one study is needed.
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